Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease

Nature Reviews Drug Discovery

Volumn 12, Issue 4, 2013, Pages 324-

  Aisen, Paul S ^a   Vellas, Bruno ^b   Hampel, Harald ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AVAGACESTAT; BAPINEUZUMAB; MEMANTINE; SEMAGACESTAT; SOLANEZUMAB;

ALZHEIMER DISEASE; AMYLOIDOSIS; AUTOSOMAL DOMINANT DISORDER; CLINICAL TRIAL (TOPIC); DOWN SYNDROME; HUMAN; LETTER; MENTAL PERFORMANCE; MOLECULARLY TARGETED THERAPY; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CEREBROSPINAL FLUID LEVEL; SECONDARY PREVENTION;

ALZHEIMER DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 84875697254     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3842-c1     Document Type: Letter

References (10)

1. Mullard, A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nature Rev. Drug Discov. 11, 657-660 (2012).
2. Sperling, R. et al. A randomized, double-blind placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E ε4 carriers. European Federation of Neurological Societies [online], http://www2.kenes.com/efns/info/ Documents/Sperling- Bapineuzumab%20IV%20Study%20302-EFNS%20 Presentation%20Slides-9-11-2012.pdf (Stockholm, Sweden; 2012).
3. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002).
4. Sperling, R. A., Jack, C. R. & Aisen, P. S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3, 111cm33 (2011).
5. Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99 (2012).
6. Sperling, R. A. et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292 (2011).
7. Hampel, H. et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nature Rev. Drug Discov. 9, 560-574 (2010).
8. Bateman, R. J. et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease; the Dominantly Inherited Alzheimer Network. N. Engl. J. Med. 367, 795-804 (2012).
9. Rowe, C. C. et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol. Aging. 31, 1275-1283 (2010).
10. Ness, S. et al. Down's syndrome and Alzheimer's disease: towards secondary prevention. Nature Rev. Drug Discov. 11, 655-656 (2012).